R&D News | pharmaphorum

News

FibroGen slumps on second failed DMD study

FibroGen has revealed that a second late-stage clinical trial of Duchenne muscular dystrophy (DMD) therapy pamrevlumab has failed to show efficacy, extending a run of bad

News

Poll finds UK pharma's rep still high post-COVID

The UK pharma industry saw a spike in public trust and favourability amid the COVID-19 pandemic that, so far, shows little sign of wearing off, according to a new poll.

News

Google builds in biotech AI with Ginkgo alliance

Google Cloud and Ginkgo Bioworks have started a five-year partnership to bring artificial intelligence to biotech in areas including genomics, protein studies, and infecti

News

BlueRock clears key hurdle in Parkinson's stem cell trial

It's a case of so far, so good for BlueRock Therapeutics' first clinical trial of Parkinson's disease therapy bemdaneprocel, with no major safety issues reported after a y

News

Semaglutide scores again, this time in heart failure

The list of benefits for Novo Nordisk's semaglutide keeps getting longer.

News

Aspen taps tech firms for digital Parkinson's trial

Aspen Neuroscience is adding a digital dimension to a study of its experimental cell therapy for Parkinson's disease, with the help of tech companies Emerald Innovations a

FibroGen slumps on second failed DMD study

Poll finds UK pharma's rep still high post-COVID

Google builds in biotech AI with Ginkgo alliance

BlueRock clears key hurdle in Parkinson's stem cell trial

Semaglutide scores again, this time in heart failure

Aspen taps tech firms for digital Parkinson's trial

On addressing drug waste and ensuring access, with Jeff Harp...

How to meet your physicians where they are online

News

Editor's Picks